CAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital))

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameCAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital))
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)
China Registration ClassN/A

Develop Information

Active CompaniesThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)
Inactive CompaniesN/A
Active IndicationsNeoplasms, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A